Hello,
Welcome to Insider Healthcare. I'm Lydia Ramsey Pflanzer, and today in healthcare news:
- The download on some mixed Alzheimer's drug results;
- Meet the startup that wants insurers to pay for seniors' groceries and meal kits;
- What we're doing wrong in the fight against COVID-19.
If you're new to this newsletter, sign up here. Comments, tips, recipes? Email me at [email protected] or tweet @lydiaramsey125. Now, let's get to it…
New data on Eli Lilly's experimental Alzheimer's drug backs a hotly debated scientific theory, but shows mixed benefits for patients
- Eli Lilly's experimental treatment slowed down cognitive decline by 32% in a midstage trial.
- But the drug missed most of the secondary trial goals, including one watched by experts.
- An Eli Lilly executive told Insider the data was mixed, but very exciting.
A new kind of healthcare startup wants health insurers to pay for meal kits and groceries for food-insecure seniors
- Project Well, a startup taking a nutritional approach to chronic disease, raised $2 million.
- The startup plans to target the booming Medicare Advantage market.
- It works with food vendors and dietitians to get patients to eat healthier and manage conditions.
The 4 things the US is doing wrong in the fight against COVID-19, and what we should be doing instead
- We've been living pandemic life for a year now.
- Insider has identified 4 ways we could be living with COVID-19 better, right now.
- Safer travel, savvier surveillance, and well-regulated masks are all areas we can improve, and the results could be huge.
More stories we're reading today:
- Germany, France, and 10 other countries have all suspended AstraZeneca's vaccine over possible side effects (Insider)
- Correctional officers are turning down vaccines (The Marshall Project)
- Facebook announced a new plan to help users make COVID-19 vaccine appointments (Insider)
- What's happening with AstraZeneca's coronavirus vaccine (Stat News)
- Lydia
Read the original article on Business Insider